MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$12,914,185
EPS
-$0.11
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Research and development
8,393,789
16,595,680*
4,036,267
2,819,377
General and administrative
6,617,238
11,681,542*
6,291,079
7,401,929
Total operating expenses
15,011,027
28,277,222
10,327,346
10,221,306
Loss from operations
-15,011,027
-28,277,222*
-10,327,346
-10,221,306
Interest/investment income, net
2,301,394
543,282.5*
247,013
321,458
Realized (loss) gain on short-term investments
-37,294
-27,854.5*
-81,438
47,203
Unrealized (loss) gain on short-term investments
-167,258
313,538*
70,275
-13,797
Total other income
2,096,842
828,966*
235,850
354,864
Net loss
-12,914,185
-27,448,256
-10,091,496
-9,866,442
Basic EPS
-0.11
-0.527
-0.3
-0.3
Diluted EPS
-0.11
-0.527
-0.3
-0.3
Basic Average Shares
112,375,941
52,055,838
33,191,622
33,191,622
Diluted Average Shares
112,375,941
52,055,838
33,191,622
33,191,622
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Interest/investment income, net
$2,301,394
(615.92%↑ Y/Y)
Net loss
-$12,914,185
(-30.89%↓ Y/Y)
Total other income
$2,096,842
(490.89%↑ Y/Y)
Unrealized (loss) gain on
short-term investments
-$167,258
(-1112.28%↓ Y/Y)
Realized (loss) gain on
short-term investments
-$37,294
(-179.01%↓ Y/Y)
Loss from operations
-$15,011,027
(-46.86%↓ Y/Y)
Total operating
expenses
$15,011,027
(46.86%↑ Y/Y)
Research and development
$8,393,789
(197.72%↑ Y/Y)
General and
administrative
$6,617,238
(-10.60%↓ Y/Y)
Buy us a coffee
RELMADA THERAPEUTICS, INC. (RLMD)
RELMADA THERAPEUTICS, INC. (RLMD)